A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis
Phase of Trial: Phase I/II
Latest Information Update: 22 Feb 2019
At a glance
- Drugs Ruxolitinib (Primary) ; Sonidegib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 07 Jul 2018 Status changed from active, no longer recruiting to completed.
- 22 May 2018 The study has been discontinued in United Kingdom.
- 29 Apr 2018 The study has been Discontinued in France.